Agnostic drug development revisited

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Molecular profiling and next-generation sequencing (NGS) have revolutionized oncology.
• Tumor-agnostic drug approvals, like pembrolizumab for MSI-High tumors, are increasing.
• Targeted therapies are becoming a cornerstone of cancer treatment.

Purpose of the Study:

• To review current tumor-agnostic drug approvals in oncology.
• To identify promising candidate therapeutics for tumor-agnostic designation.
• To discuss challenges in the broad implementation of these therapies.

Main Methods:

• Literature review of current tumor-agnostic approvals.
• Analysis of emerging molecular targets and candidate therapeutics.
• Discussion of drug development and clinical implementation challenges.

Main Results:

• An overview of FDA-approved tumor-agnostic therapies is presented.
• Several promising molecular targets and associated therapeutics are highlighted.
• Key challenges in drug development and clinical integration are identified.

Conclusions:

• The landscape of tumor-agnostic cancer therapy is rapidly evolving.
• Addressing challenges in drug development and implementation is crucial for expanding patient access.
• Continued research and collaboration are essential for advancing precision oncology.